CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Arana Therapeutics Limited is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Arana Therapeutics Limited
Level 2, 37 Epping Road
Phone: (2) 806-19900p:2 806-19900 Macquarie Park, NSW  2113  Australia Ticker: AAH AAH

This company was Merged or Acquired on 8/10/2009.
This company is no longer actively traded on any major stock exchange.

Business Summary
Arana Therapeutics Limited (Arana) is engaged in the commercialization of research, development, investment in, and licensing of technology, and the formulation, manufacture and marketing of protein-based products for the pharmaceutical industry. ART621 is a new type of therapeutic protein, which incorporates a domain antibody (dAb) and is the first compound incorporating a domain antibody to be used in human trials. PMX53 is a complement 5a (C5a) inhibitor. Arana has developed a new antibody candidate, ART 123 targeting the inflammatory diseases. ART010 is aimed at treating the side-effects of cancer known as cancer-related bone loss. ART104 is an antibody in development for the treatment of colorectal cancer. ART150 is an antibody under development for the treatment of lung cancer and melanoma. In August 2009, Cephalon, Inc. completed the acquisition of Arana Therapeutics Limited.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/20099/30/2008Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board FrankBaldino 56 5/28/2009 5/28/2009
Acting Chief Executive Officer; President of Arana Therapeutics Inc. SteffenNock 11/12/2008 8/28/2007
Chief Financial Officer, Company Secretary NiallHenderson 1/1/2001 1/1/2001
9 additional Officers and Directors records available in full report.

Business Names
Business Name
AAH
Arana Therapeutics Limited
Peptech Limited

General Information
Number of Employees: 21 (As of 9/30/2005)
Outstanding Shares: 227,655,322 (As of 3/31/2009)
Shareholders: 11,555
Stock Exchange: ASX
Fax Number: (2) 806-19999


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023